Luye Pharma Group (FRA:LUP) Tariff Resilience Score: 4/10 (As of Jul. 07, 2026)


FRA:LUP Luye Pharma Group Ltd FRA:LUP
47 GF Score
Price €0.22
GF Value €0.36
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group Tariff Resilience Score?

Luye Pharma Group FRA:LUP +3.70% 47 Tariff Resilience Score is 4 as of Jul. 07, 2026. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.36 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Luye Pharma Group ranks better than 79.71% on this metric.

Luye Pharma Group has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Luye Pharma Group has Luye Pharma's global operations and reliance on international markets for both supply and sales increase tariff vulnerability. The pharmaceutical industry may offer some exemptions, but supply chain dependencies pose significant risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Luye Pharma Group might have Average Resilient.

Luye Pharma Group  (FRA:LUP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Luye Pharma Group Tariff Resilience Score Related Terms

FRA:LUP vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Tariff Resilience Score falls into.


FRA:LUP
47GF Score
Luye Pharma Group Ltd FRA:LUP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Luye Pharma Group (FRA:LUP) has a Tariff Resilience Score of 4 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Luye Pharma Group ranks #209 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Luye Pharma Group's Tariff Resilience Score too high?
Luye Pharma Group's current Tariff Resilience Score is 4. Based on the distribution chart, Luye Pharma Group ranks #209 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #209 out of 1030 companies for Tariff Resilience Score. This places Luye Pharma Group in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Luye Pharma Group's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.22 — trading 37.8% below its estimated fair value. The current Tariff Resilience Score is 4. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Tariff Resilience Score is 4 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of €0.22 is trading 37.8% below its estimated GF Value™ of €0.36. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:LUP:

  • Tariff Resilience Score: 4
  • GF Value™: €0.36 vs. price of €0.22 (37.8% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges LYPHF:USA02186:Hong Kong
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score

Get the complete analysis for FRA:LUP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.22
Price
€0.36
GF Value